Long-term CB1 receptor blockade enhances vulnerability to anxiogenic-like effects of cannabinoids

Neuropharmacology

Volumn 70, Issue , 2013, Pages 268-277

  Tambaro, Simone ^a,b   Tomasi, Maria Lauda ^c   Bortolato, Marco ^d  

^a Neuroscienze PharmaNess Scarl   (Italy)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF KANSAS   (United States)

Author keywords

Anxiety; Cannabinoid CB1 receptors; Prefrontal cortex; Striatum

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID; CANNABINOID 1 RECEPTOR; 3-(2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL)-4-(3-HYDROXYPROPYL)CYCLOHEXANOL; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CYCLOHEXANOL DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOWN REGULATION; HIPPOCAMPUS; IMMUNOBLOTTING; MALE; MAZE TEST; MESENCEPHALON; MOUSE; NONHUMAN; OPEN FIELD TEST; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; REARING; SOCIAL INTERACTION; TRANQUILIZING ACTIVITY; UPREGULATION; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; BRAIN; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; METABOLISM;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BRAIN; CANNABINOID RECEPTOR AGONISTS; CANNABINOID RECEPTOR ANTAGONISTS; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG INTERACTIONS; MALE; MICE; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; UP-REGULATION;

EID: 84877004880     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.02.009     Document Type: Article

References (59)

1. V.C. Anseloni, N.C. Coimbra, S. Morato, and M.L. Brandão A comparative study of the effects of morphine in the dorsal periaqueductal gray and nucleus accumbens of rats submitted to the elevated plus-maze test Exp. Brain Res. 129 1999 260 268
2. F. Berrendero, and R. Maldonado Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol Psychopharmacology (Berl.) 163 2002 111 117
3. F. Berrendero, N. Sepe, J.A. Ramos, V. Di Marzo, and J.J. Fernandez-Ruiz Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period Synapse 33 1999 181 191
4. S. Bishop, J. Duncan, M. Brett, and A.D. Lawrence Prefrontal cortical function and anxiety: controlling attention to threat-related stimuli Nat. Neurosci. 7 2004 184 188
5. M. Bortolato, V. Bini, and S. Tambaro Vulnerability factors for the psychiatric and behavioral effects of cannabis Pharmaceuticals 3 2010 2799 2820
6. M. Bortolato, K. Chen, S.C. Godar, G. Chen, W. Wu, I. Rebrin, M.R. Farrell, A.L. Scott, C.L. Wellman, and J.C. Shih Social deficits and perseverative behaviors, but not overt aggression, in MAO-A hypomorphic mice Neuropsychopharmacology 2011
7. M. Bortolato, S.C. Godar, S. Davarian, K. Chen, and J.C. Shih Behavioral disinhibition and reduced anxiety-like behaviors in monoamine oxidase B-deficient mice Neuropsychopharmacology 34 2009 2746 2757
8. M. Bortolato, R.A. Mangieri, J. Fu, J.H. Kim, O. Arguello, A. Duranti, A. Tontini, M. Mor, G. Tarzia, and D. Piomelli Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress Biol. Psychiatry 62 2007 1103 1110
9. M. Bortolato, and D. Piomelli The endocannabinoid system and anxiety responses Handbook of Behavioral Neuroscience Handbook of Anxiety and Fear vol. 17 2008 Elsevier Amsterdam, Netherlands (Chapter 4.5, pp. 303-324)
10. D. Braida, V. Limonta, L. Malabarba, A. Zani, and M. Sala 5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats Eur. J. Pharmacol. 555 2007 156 163
11. E. Celerier, T. Ahdepil, H. Wikander, F. Berrendero, F. Nyberg, and R. Maldonado Influence of the anabolic-androgenic steroid nandrolone on cannabinoid dependence Neuropharmacology 50 2006 788 806
12. A. Chakrabarti, J.E. Ekuta, and E.S. Onaivi Neurobehavioral effects of anandamide and cannabinoid receptor gene expression in mice Brain Res. Bull. 45 1998 67 74
13. A.P. Chambers, H.S. Koopmans, Q.J. Pittman, and K.A. Sharkey AM 251 produces sustained reductions in food intake and body weight that are resistant to tolerance and conditioned taste aversion Br. J. Pharmacol. 147 2006 109 116
14. R.Z. Chen, R.R. Huang, C.P. Shen, D.J. MacNeil, and T.M. Fong Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice Brain Res. 999 2004 227 230
15. J.A. Crippa, A.W. Zuardi, R. Martin-Santos, S. Bhattacharyya, Z. Atakan, P. McGuire, and P. Fusar-Poli Cannabis and anxiety: a critical review of the evidence Hum. Psychopharmacol. 24 2009 515 523
16. R.J. Davidson Anxiety and affective style: role of prefrontal cortex and amygdala Biol. Psychiatry 51 2002 68 80
17. E.A. Del Bel, and F.S. Guimaraes Sub-chronic inhibition of nitric-oxide synthesis modifies haloperidol-induced catalepsy and the number of NADPH-diaphorase neurons in mice Psychopharmacology (Berl.) 147 2000 356 361
18. J.M. Fuster The prefrontal cortex-an update: time is of the essence Neuron 30 2001 319 333
19. R.F. Genn, S. Tucci, E.M. Marco, M.P. Viveros, and S.E. File Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test Pharmacol. Biochem. Behav. 77 2004 567 573
20. S. Gonzalez, M.G. Cascio, J. Fernandez-Ruiz, F. Fezza, V. Di Marzo, and J.A. Ramos Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine Brain Res. 954 2002 73 81
21. J.R. Gray, T.S. Braver, and M.E. Raichle Integration of emotion and cognition in the lateral prefrontal cortex Proc. Natl. Acad. Sci. U. S. A. 99 2002 4115 4120
22. B. Green, D. Kavanagh, and R. Young Being stoned: a review of self-reported cannabis effects Drug Alcohol. Rev. 22 2003 453 460
23. N. Hajos, and T.F. Freund Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers Neuropharmacology 43 2002 503 510
24. J. Haller, B. Varga, C. Ledent, and T.F. Freund CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents Behav. Pharmacol. 15 2004 299 304
25. M. Herkenham, A.B. Lynn, M.R. Johnson, L.S. Melvin, B.R. de Costa, and K.C. Rice Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study J. Neurosci. 11 1991 563 583
26. M. Herkenham, A.B. Lynn, M.D. Little, M.R. Johnson, L.S. Melvin, B.R. de Costa, and K.C. Rice Cannabinoid receptor localization in brain Proc. Natl. Acad. Sci. U. S. A. 87 1990 1932 1936
27. M.N. Hill, and B.B. Gorzalka Enhancement of anxiety-like responsiveness to the cannabinoid CB(1) receptor agonist HU-210 following chronic stress Eur. J. Pharmacol. 499 2004 291 295
28. C. Hsieh, S. Brown, C. Derleth, and K. Mackie Internalization and recycling of the CB1 cannabinoid receptor J. Neurochem. 73 1999 493 501
29. I. Katona, E.A. Rancz, L. Acsady, C. Ledent, K. Mackie, N. Hajos, and T.F. Freund Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission J. Neurosci. 21 2001 9506 9518
30. K.S. Kendler, K.C. Jacobson, C.A. Prescott, and M.C. Neale Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins Am. J. Psychiatry 160 2003 687 695
31. R. Lan, Q. Liu, P. Fan, S. Lin, S.R. Fernando, D. McCallion, R. Pertwee, and A. Makriyannis Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists J. Med. Chem. 42 1999 769 776
32. J. Lazary, A. Lazary, X. Gonda, A. Benko, E. Molnar, L. Hunyady, G. Juhasz, and G. Bagdy Promoter variants of the cannabinoid receptor 1 gene (CNR1) in interaction with 5-HTTLPR affect the anxious phenotype Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B 2009 1118 1127
33. R. Maldonado Study of cannabinoid dependence in animals Pharmacol. Ther. 95 2002 153 164
34. R. Maldonado, and F. Rodriguez de Fonseca Cannabinoid addiction: behavioral models and neural correlates J. Neurosci. 22 2002 3326 3331
35. J. Manzanares, L. Uriguen, G. Rubio, and T. Palomo Role of endocannabinoid system in mental diseases Neurotox. Res. 6 2004 213 224
36. E.M. Marco, L. Perez-Alvarez, E. Borcel, M. Rubio, C. Guaza, E. Ambrosio, S.E. File, and M.P. Viveros Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats Behav. Pharmacol. 15 2004 21 27
37. I.S. McGregor, C.N. Issakidis, and G. Prior Aversive effects of the synthetic cannabinoid CP 55,940 in rats Pharmacol. Biochem. Behav. 53 1996 657 664
38. C.R. McLaughlin, B.R. Martin, D.R. Compton, and M.E. Abood Cannabinoid receptors in developing rats: detection of mRNA and receptor binding Drug Alcohol Depend. 36 1994 27 31
39. E.K. Miller, and J.D. Cohen An integrative theory of prefrontal cortex function Annu. Rev. Neurosci. 24 2001 167 202
40. K.N. Ochsner, J.S. Beer, E.R. Robertson, J.C. Cooper, J.D. Gabrieli, J.F. Kihsltrom, and M. D'Esposito The neural correlates of direct and reflected self-knowledge Neuroimage 28 2005 797 814
41. E.S. Onaivi, A. Chakrabarti, E.T. Gwebu, and G. Chaudhuri Neurobehavioral effects of delta 9-THC and cannabinoid (CB1) receptor gene expression in mice Behav. Brain Res. 72 1995 115 125
42. E.S. Onaivi, M.R. Green, and B.R. Martin Pharmacological characterization of cannabinoids in the elevated plus maze J. Pharmacol. Exp. Ther. 253 1990 1002 1009
43. S. Ortiz, J.M. Oliva, S. Perez-Rial, T. Palomo, and J. Manzanares Differences in basal cannabinoid CB1 receptor function in selective brain areas and vulnerability to voluntary alcohol consumption in Fawn Hooded and Wistar rats Alcohol Alcohol. 39 2004 297 302
44. S. Patel, and C.J. Hillard Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling J. Pharmacol. Exp. Ther. 318 2006 304 311
45. M.L. Phillips, L.J. Gregory, S. Cullen, S. Coen, V. Ng, C. Andrew, V. Giampietro, E. Bullmore, F. Zelaya, E. Amaro, D.G. Thompson, A.R. Hobson, S.C. Williams, M. Brammer, and Q. Aziz The effect of negative emotional context on neural and behavioural responses to oesophageal stimulation Brain 126 2003 669 684
46. M. Pratte, and M. Jamon Detection of social approach in inbred mice Behav. Brain Res. 203 2009 54 64
47. K. Ramani, H. Yang, M. Xia, A.I. Ara, J.M. Mato, and S.C. Lu Leptin's mitogenic effect in human liver cancer cells requires induction of both methionine adenosyltransferase 2A and 2beta Hepatology 47 2008 521 531
48. A.A. Rey, M. Purrio, M.P. Viveros, and B. Lutz Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA(B) receptors in the balance of GABAergic and glutamatergic neurotransmission Neuropsychopharmacology 37 2012 2624 2634
49. R.J. Rodgers, C. Lee, and J.K. Shepherd Effects of diazepam on behavioural and antinociceptive responses to the elevated plus-maze in male mice depend upon treatment regimen and prior maze experience Psychopharmacology (Berl.) 106 1992 102 110
50. F. Rodriguez de Fonseca, P. Rubio, F. Menzaghi, E. Merlo-Pich, J. Rivier, G.F. Koob, and M. Navarro Corticotropin-releasing factor (CRF) antagonist [D-Phe12, Nle21,38, C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats J. Pharmacol. Exp. Ther. 276 1996 56 64
51. T. Rubino, N. Realini, C. Castiglioni, C. Guidali, D. Vigano, E. Marras, S. Petrosino, G. Perletti, M. Maccarrone, V. Di Marzo, and D. Parolaro Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex Cereb. Cortex 18 2008 1292 1301
52. K.A. Seely, L.K. Brents, L.N. Franks, M. Rajasekaran, S.M. Zimmerman, W.E. Fantegrossi, and P.L. Prather AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies Neuropharmacology 63 2012 905 915
53. Substance Abuse and Mental Health Services Administration Results from the 2008 National Survey on Drug Use and Health: National Findings 2009 Office of Applied Studies Rockville, MD, USA NSDUH Series H-36, HHS Publication No. SMA 09-4434
54. S. Tambaro, and M. Bortolato Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives Recent Pat. CNS Drug Discov. 7 2012 25 40
55. D. Treit, and M. Fundytus Thigmotaxis as a test for anxiolytic activity in rats Pharmacol. Biochem. Behav. 31 1988 959 962
56. E. Valjent, J.M. Mitchell, M.J. Besson, J. Caboche, and R. Maldonado Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine Br. J. Pharmacol. 135 2002 564 578
57. K.J. Verweij, B.P. Zietsch, M.T. Lynskey, S.E. Medland, M.C. Neale, N.G. Martin, D.I. Boomsma, and J.M. Vink Genetic and environmental influences on cannabis use initiation and problematic use: a meta-analysis of twin studies Addiction 105 2010 417 430
58. R.C. Wilson, T. Vacek, D.L. Lanier, and D.A. Dewsbury Open-field behavior in muroid rodents Behav. Biol. 17 1976 495 506
59. D. Zhou, and L.P. Shearman Voluntary exercise augments acute effects of CB1-receptor inverse agonist on body weight loss in obese and lean mice Pharmacol. Biochem. Behav. 77 2004 117 125